Chan BS, Mirabella J, Allen K, Berling I, Chiew AL, Isoardi K, et al. Tapentadol exposures and poisonings in Australia. Clin Toxicol (Phila) 2022;60(9):1063-6. https://www.ncbi.nlm.nih.gov/pubmed/35670823
Dassanayake TL, Jones AL, Michie PT, Carter GL, McElduff P, Stokes BJ, et al. Risk of road traffic accidents in patients discharged following treatment for psychotropic drug overdose: a self-controlled case series study in Australia. CNS Drugs 2012;26(3):269-76. https://www.ncbi.nlm.nih.gov/pubmed/22329565
Dassanayake TL, Michie PT, Jones AL, Mallard T, Whyte IM, Carter GL. Cognitive skills underlying driving in patients discharged following self-poisoning with central nervous system depressant drugs. Traffic Inj Prev 2012;13(5):450-7. https://www.ncbi.nlm.nih.gov/pubmed/22931174
Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit 2008;30(4):490-6. https://www.ncbi.nlm.nih.gov/pubmed/18641540
Gressler LE. Serotonin syndrome in tapentadol literature: systematic review of original research. J Pain Palliat Care Pharmacother 2017;31:228-36. https://www.ncbi.nlm.nih.gov/pubmed/29336654
Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R, Keegan F, et al.
Pharmacokinetic properties and human use characteristics of an FDA-approved
intranasal naloxone product for the treatment of opioid overdose. J Clin
Pharmacol 2016;56(10):1243–53. https://www.ncbi.nlm.nih.gov/pubmed/27145977
Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf 2018;9(1):63-88. https://www.ncbi.nlm.nih.gov/pubmed/29318006
